Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

252 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.
Winter GE, Rix U, Carlson SM, Gleixner KV, Grebien F, Gridling M, Müller AC, Breitwieser FP, Bilban M, Colinge J, Valent P, Bennett KL, White FM, Superti-Furga G. Winter GE, et al. Nat Chem Biol. 2012 Nov;8(11):905-912. doi: 10.1038/nchembio.1085. Epub 2012 Sep 30. Nat Chem Biol. 2012. PMID: 23023260 Free PMC article.
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.
Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, Gish GD, Cerny-Reiterer S, Koide A, Beug H, Pawson T, Valent P, Koide S, Superti-Furga G. Grebien F, et al. Cell. 2011 Oct 14;147(2):306-19. doi: 10.1016/j.cell.2011.08.046. Cell. 2011. PMID: 22000011 Free PMC article.
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
Hantschel O, Rix U, Schmidt U, Bürckstümmer T, Kneidinger M, Schütze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G. Hantschel O, et al. Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8. doi: 10.1073/pnas.0702654104. Epub 2007 Aug 7. Proc Natl Acad Sci U S A. 2007. PMID: 17684099 Free PMC article.
252 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page